Ipsen and Medetia join forces to accelerate early research in rare disease

In keeping with Ipsen’s drive to accelerate the research and development of transformative therapies, we are pleased to announce a new research collaboration agreement with Medetia, a biotech with extensive drug discovery and medicinal chemistry experience, located at the Imagine Institute in Paris. Through this collaboration we hope to collectively bring new solutions to people around the world, with a focus on rare diseases including rare neurodegenerative disorders. We remain steadfast in our focused expansion, as we continue to build our pipeline at every stage, advancing the promise of innovative new therapies across Ipsen’s three focus areas of oncology, rare disease and neuroscience.

“We’re delighted to be partnering with Medetia to continue accelerating the development of next-generation transformative solutions for rare disease”, said Christelle Huguet, SVP, Head of Research, External Innovation and Early Development. “At Ipsen, we believe that great partnerships create great possibilities. By joining the collective R&D firepower of Ipsen and the extensive drug discovery and medicinal chemistry experience of Medetia, we hope to break the limits of current clinical understanding, to bring treatments for people living with rare diseases. We have been deeply committed to improving outcomes for people living with cancer, rare disease and neurological conditions for the past 100 years and, leveraging our precision focus, we will continue for the next 100.”

This partnership brings together Medetia for its expertise in prospecting and experimental evaluation and management in novel therapies for rare disease and rare neurodegenerative disorders through rights granted by Inserm Transfert to Medetia for its cutting-edge innovative therapeutic proposals, and Ipsen for its strong capacity to develop transformative medicines for people living with rare and severe diseases. Medetia will be responsible for activities up to candidate selection. Ipsen will have the option to secure exclusive worldwide rights for any successful candidates and will then be responsible for all development and commercialization.

Working with partners, such as Medetia, affords us the opportunity to explore potential candidates developed through their team’s exceptional expertise and partnerships with Inserm Transfert and Institute Imagine, as we continue to build a robust pipeline at every stage. Fuelled by collaborations like these, we hope to see more candidates progress into clinical development and, eventually, be made available to patients around the world. This agreement forms the latest in a long line of external partnerships to strengthen our pursuit of external innovation in life sciences as part of our growth strategy, deepening our commitment to improving outcomes for people living with cancer, rare disease and neurological conditions.

Related Statements